SCHEMBL352339

SCHEMBL352339

CC(=O)c1ccc(C#N)s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.56
MAPT P10636 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
LMNA P02545 3/20 0.47
TSHR P16473 1/20 0.47
GSK3B P49841 1/20 0.46
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
HDAC8 Q9BY41 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2A6 P11509 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
S1PR1 P21453 2/20 0.38
S1PR3 Q99500 2/20 0.38
S1PR2 O95136 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8588619 0.83 L3MBTL1 (0.70) L3MBTL1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3960184 0.81 DAO (0.48) L3MBTL1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL6211351 0.81 L3MBTL1 (0.58) L3MBTL1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL10638684 0.79 S1PR1 (0.41) L3MBTL1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL22711381 0.79 HDAC8 (0.63) L3MBTL1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL7205892 0.79 F2 (0.52) L3MBTL1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15113608 0.79 S1PR1 (0.39) L3MBTL1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL20786824 0.79 KDM4E (0.49) L3MBTL1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2226439 0.79 NPSR1 (0.51) L3MBTL1MAPTSMN1; SMN2LMNATSHR
SCHEMBL2872059 0.77 GSK3B (0.67) L3MBTL1MAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118448723-A Sodium ion battery electrolyte, preparation method thereof and sodium ion battery 广州鹏辉能源科技股份有限公司 2024-08-06 CN claimed
CN-115425292-B High-temperature-resistant electrolyte, secondary battery and application thereof 华中科技大学 2024-07-23 CN claimed
CN-115425292-A High-temperature-resistant electrolyte, secondary battery and application thereof 华中科技大学 2022-12-02 CN claimed
CN-118448723-A Sodium ion battery electrolyte, preparation method thereof and sodium ion battery 广州鹏辉能源科技股份有限公司 2024-08-06 CN disclosed
CN-118448723-A Sodium ion battery electrolyte, preparation method thereof and sodium ion battery 广州鹏辉能源科技股份有限公司 2024-08-06 CN disclosed
CN-115425292-B High-temperature-resistant electrolyte, secondary battery and application thereof 华中科技大学 2024-07-23 CN disclosed
CN-117177970-A Polycyclic derivative regulator, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-12-05 CN disclosed
US-20230257395-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-08-17 US disclosed
US-20230257395-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-08-17 US disclosed
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed
EP-0879223-A1 AROMATIC POLYCYCLIC RETINOID-TYPE DERIVATIVES, METHOD FOR PREPARING SAME, AND USE THEREOF FOR MAKING PHARMACEUTICAL AND COSMETIC COMPOSITIONS Centre Europeen de Bioprospective -CEB (FR) 1998-11-25 EP disclosed
WO-1997026237-A1 AROMATIC POLYCYCLIC RETINOID-TYPE DERIVATIVES, METHOD FOR PREPARING SAME, AND USE THEREOF FOR MAKING PHARMACEUTICAL AND COSMETIC COMPOSITIONS CENTRE EUROPEEN DE BIOPROSPECTIVE - CEB (FR) 1997-07-24 WO disclosed
EP-0245835-B1 NOVEL THIOPHENE DERIVATIVES AND METHODS FOR PRODUCING THE SAME SEITETSU KAGAKU CO., LTD. (JP) 1993-05-05 EP disclosed
US-5101049-A Novel thiophene derivatives and methods for producing the same SEITETSU KAGAKU CO., LTD. (JP) 1992-03-31 US disclosed
US-4792612-A MEDICINE INTERMEDIATES SEITETSU KAGAKU CO., LTD. (JP) 1988-12-20 US disclosed
EP-0245835-A2 Novel thiophene derivatives and methods for producing the same SEITETSU KAGAKU CO., LTD. (JP) 1987-11-19 EP disclosed
US-4341957-A Fluorescent antibody composition for immunofluorometric assay ANALYTICAL RADIATION CORPORATION (US) 1982-07-27 US disclosed
US-4153610-A Process for producing 5-carboxy-2-acetylthiophene SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1979-05-08 US disclosed
US-4130566-A Process for producing 5-carboxy-2-acetylthiophene SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1978-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257395-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS TRPA1, TRPV1, TRPV5 L3MBTL1 3924/4885MAPT 365/4885NPC1 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.